Zobrazeno 1 - 10
of 67
pro vyhledávání: '"Susan L Rosenkranz"'
Autor:
Nicholas T Funderburg, Adriana Andrade, Ellen S Chan, Susan L Rosenkranz, Darlene Lu, Brian Clagett, Heather A Pilch-Cooper, Benigno Rodriguez, Judith Feinberg, Eric Daar, John Mellors, Daniel Kuritzkes, Jeffrey M Jacobson, Michael M Lederman
Publikováno v:
PLoS ONE, Vol 8, Iss 12, p e83514 (2013)
The dynamics of CD4+ T cell reconstitution and changes in immune activation and inflammation in HIV-1 disease following initiation of antiretroviral therapy (ART) are incompletely defined and their underlying mechanisms poorly understood.Thirty-nine
Externí odkaz:
https://doaj.org/article/3b58f04f006740d5be4622a96fcb8721
Autor:
Kamunkhwala Gausi, Maxwell Chirehwa, Elisa H Ignatius, Richard Court, Xin Sun, Laura Moran, Richard Hafner, Lubbe Wiesner, Susan L Rosenkranz, Veronique de Jager, Nihal de Vries, Joseph Harding, Tawanda Gumbo, Susan Swindells, Andreas Diacon, Kelly E Dooley, Helen McIlleron, Paolo Denti
Publikováno v:
J Antimicrob Chemother
Background The WHO-endorsed shorter-course regimen for MDR-TB includes high-dose isoniazid. The pharmacokinetics of high-dose isoniazid within MDR-TB regimens has not been well described. Objectives To characterize isoniazid pharmacokinetics at 5–1
Autor:
Dmitriy M. Martirosov, Monique R. Bidell, Manjunath P. Pai, Marc H. Scheetz, Susan L. Rosenkranz, Corey Faragon, M. Malik, R. E. Mendes, R. N. Jones, Louise-Anne McNutt, Thomas P. Lodise
Publikováno v:
BMC Infectious Diseases, Vol 17, Iss 1, Pp 1-7 (2017)
Abstract Background In vitro data suggests that suboptimal initial vancomycin exposure may select for heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) infections. However, no clinical studies have evaluated the relationship between
Externí odkaz:
https://doaj.org/article/f084be5c41784487b40cdab60246cae4
Autor:
Laura Moran, Elisa H. Ignatius, Susan Swindells, Paolo Denti, Richard Hafner, Florian von Groote-Bidlingmaier, Eric L. Nuermberger, Naadira Vanker, Soyeon Kim, Andreas H. Diacon, Kathleen Donahue, Kelly E. Dooley, Susan L. Rosenkranz, Kamunkhwala Gausi, Xin Sun, Lubbe Wiesner
Publikováno v:
American Journal of Respiratory and Critical Care Medicine. 204:1327-1335
Rationale: There is accumulating evidence that higher-than-standard doses of isoniazid are effective against low-to-intermediate-level isoniazid-resistant strains of Mycobacterium tuberculosis, but...
Autor:
Lénaïg Tanneau, Mats O. Karlsson, Susan L. Rosenkranz, Yoninah S. Cramer, Justin Shenje, Caryn M. Upton, Joel Morganroth, Andreas H. Diacon, Gary Maartens, Kelly E. Dooley, Elin M. Svensson
Publikováno v:
Clinical Pharmacology and Therapeutics, 112, 4, pp. 873-881
Clinical Pharmacology and Therapeutics, 112, 873-881
Clinical Pharmacology and Therapeutics, 112, 873-881
Contains fulltext : 283109.pdf (Publisher’s version ) (Open Access) Delamanid and bedaquiline are two drugs approved to treat drug-resistant tuberculosis, and each have been associated with corrected QT interval (QTc) prolongation. We aimed to inve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32ed03bf64f4a744727831d5274ee59e
https://repository.ubn.ru.nl/handle/2066/283109
https://repository.ubn.ru.nl/handle/2066/283109
Autor:
Kelly E. Dooley, Sachiko Miyahara, Florian von Groote-Bidlingmaier, Xin Sun, Richard Hafner, Susan L. Rosenkranz, Elisa H. Ignatius, Eric L. Nuermberger, Laura Moran, Kathleen Donahue, Susan Swindells, Naadira Vanker, Andreas H. Diacon, Rachel Issa, Christopher Lane, Mark Lojacono, Rachel Mahachi, William Murtaugh, Lynette Purdue, Akbar Shahkolahi, Ronald Ssenyonga
Publikováno v:
Am J Respir Crit Care Med
Rationale: High-dose isoniazid is recommended in short-course regimens for multidrug-resistant tuberculosis (TB). The optimal dose of isoniazid and its individual contribution to efficacy against T...
Autor:
Beverly Alston-Smith, Jeffrey Schmidt, David L. Wyles, Charles S. Venuto, Yoninah S Cramer, Mark S. Sulkowski, Gene D. Morse, Susan L. Rosenkranz, Daniel E. Cohen
Publikováno v:
Br J Clin Pharmacol
Aims AIDS Clinical Trials Group study A5334s evaluated the pharmacokinetics of raltegravir before and during combined administration of ombitasvir, paritaprevir/ritonavir, plus dasabuvir (OBV/PTV/r + DSV) and weight-based ribavirin in human immunodef
Autor:
David Shugarts, Mariam Aziz, Susan E. Cohn, Yoninah S Cramer, Carmen D. Zorrilla, Ruth Khalili Friedman, Alan L. Landay, Laura Moran, Kimberly K. Scarsi, Kristine Coughlin, Nahida Chakhtoura, Shobha Swaminathan, Baiba Berzins, Liz Barr, Victor Akelo, David W. Haas, Andee Fox, Christina Blanchard-Horan, Thucuma Sise, G T Spear, Elizabeth Connick, Francesca T. Aweeka, Mey Leon, Kristine B. Patterson, Susan L. Rosenkranz, Charles R. Wira, Mary Allegra Cermak, Cecelia Chang-Ching, David Gingrich, Pamela Tshandu, Jeong-Gun Park, Catherine Godfrey, Robert W. Coombs
Publikováno v:
The Lancet HIV. 6:e601-e612
Summary Background Drug-drug interactions between orally administered antiretroviral therapy (ART) and hormones released from an intravaginal ring are not known. We hypothesised that ART containing either efavirenz or ritonavir-boosted atazanavir wou
Autor:
Gene D. Morse, Charlene R Taylor, Richard W. Browne, Robin DiFrancesco, Yan Wang, Susan L. Rosenkranz
Publikováno v:
Ther Drug Monit
BACKGROUND: The Clinical Pharmacology Quality Assurance (CPQA) program provides semi-annual proficiency testing of antiretroviral analytes for eleven U.S. and international clinical pharmacology laboratories to ensure inter-laboratory comparability.
Autor:
Susan Swindells, Rachel Mahachi, Florian von Groote-Bidlingmaier, Caryn Upton, William Murtaugh, Richard Hafner, Laura Moran, Xin Sun, Sachiko Miyahara, Solomon P. le Roux, Susan L. Rosenkranz, Andreas H. Diacon, Kathleen Donahue, Naadira Vanker, Kelly E. Dooley, Akbar Shahkolahi, Ronald Ssenyonga, Lynette Purdue, Eric L. Nuermberger, Mark Lojacono, Rachel Issa, Elisa H. Ignatius, Christopher Lane
Publikováno v:
Am J Respir Crit Care Med
Rationale: High-dose isoniazid is recommended in short-course regimens for multidrug-resistant tuberculosis (TB). The optimal dose of isoniazid and its individual contribution to efficacy against TB strains with inhA or katG mutations are unknown. Ob